HGF-Modulating Compounds for Fibrosis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for fibrosis lack effective modulation of hepatocyte growth factor (HGF) signaling, which is crucial for managing fibrotic diseases across various tissues.

Innovation Solution

Development of compounds that modulate HGF activity to treat fibrosis, including specific chemical structures and their administration for therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies for fibrosis are used, then treatment is provided, but HGF signaling is not effectively modulated

Engineering Contradiction:

Improveeffectiveness of HGF signaling modulationVSAvoidfibrosis treatment efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the chemical structure of HGF analogs by changing parameters such as amino acid sequences, molecular weight, and post-translational modification patterns to enhance binding affinity to MET receptor and improve signaling modulation effectiveness

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite therapeutic formulations combining HGF analogs with adjuvants, delivery vehicles, or combination therapies to enhance the overall treatment efficacy and achieve effective HGF signaling modulation

Inventive Principle:

Principle #40Composite materials

2Reliability

If HGF signaling is stimulated to treat fibrosis, then antifibrotic activity is improved, but potential off-target effects and safety issues arise

Engineering Contradiction:

Improveantifibrotic activityVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs tissue-specific delivery mechanisms, targeting molecules, or conditionally active HGF analogs that activate selectively in fibrotic tissues rather than systemically, thereby achieving local antifibrotic activity while minimizing off-target effects in other organs

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention uses selective MET receptor ligands or allosteric modulators as intermediaries that selectively enhance HGF signaling at the MET receptor without activating other downstream pathways or receptors that could cause harmful off-target effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250288587A1Methods of Treating Fibrosis

Publication Date: 2025.09.18 LEONABIO INC

AI summary

Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including fibrosis.